PMID- 23206842
OWN - NLM
STAT- MEDLINE
DCOM- 20130320
LR  - 20121204
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 39
IP  - 6
DP  - 2012 Dec
TI  - Haploidentical bone marrow transplantation without T-cell depletion.
PG  - 653-63
LID - S0093-7754(12)00185-6 [pii]
LID - 10.1053/j.seminoncol.2012.09.003 [doi]
AB  - Approaches for haploidentical bone marrow transplantation (BMT) without T-cell 
      depletion have been designed using new transplant strategies, including 
      anti-thymocyte globulin (ATG) preparative regimens, granulocyte 
      colony-stimulating factor-primed grafts, post-transplantation rapamycin, or 
      high-dose cyclophosphamide (Cy) in combination with other immunosuppressive 
      agents for graft-versus-host disease (GVHD) prophylaxis. These strategies ensured 
      fast hematologic engraftment across the human leukocyte antigen (HLA) barrier 
      with an acceptable incidence of GVHD. Long-term follow-up results from different 
      transplant centers suggest that unmanipulated transplantation may provide an 
      alternative strategy in the haploidentical setting without requiring the 
      technical expertise and cost of ex vivo T-cell depletion. This review discusses 
      immune reconstitution and factors associated with clinical outcomes following 
      unmanipulated haploidentical hematopoietic stem cell transplantation (HSCT), and 
      compares outcomes between unmanipulated haploidentical transplant versus 
      HLA-matched sibling donor (MSD) transplantation, HLA-matched unrelated donor 
      (MUD) transplantation, or unrelated double umbilical cord blood (dUCB) 
      transplantation. Advantages and disadvantages of unmanipulated haploidentical 
      HSCT and strategies to improve outcome after haploidentical BMT without ex vivo 
      T-cell depletion are discussed.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing, China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
SB  - IM
MH  - Bone Marrow Transplantation/*immunology/*methods
MH  - Graft vs Host Disease/immunology/prevention & control
MH  - Haplotypes
MH  - Hematologic Neoplasms/surgery
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Histocompatibility
MH  - Humans
MH  - Lymphocyte Depletion
MH  - T-Lymphocytes/immunology
MH  - Transplantation Immunology/*immunology
MH  - Transplantation, Homologous/immunology/methods
EDAT- 2012/12/05 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/12/05 06:00
PHST- 2012/12/05 06:00 [entrez]
PHST- 2012/12/05 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - S0093-7754(12)00185-6 [pii]
AID - 10.1053/j.seminoncol.2012.09.003 [doi]
PST - ppublish
SO  - Semin Oncol. 2012 Dec;39(6):653-63. doi: 10.1053/j.seminoncol.2012.09.003.